Phase 1 study of YM155, novel selective survivin suppressant in combination with elrotinib in patients with EGFR-mutant advanced non-small-cell lung cancer - Phase 1 study of YM155 in combination with elrotinib in patients with EGFR-mutant advanced non-small-cell lung cancer

Department of Medical Oncology, Kindai University Faculty of Medicine0 个研究点目标入组 12 人开始时间: 2018年3月27日最近更新: 2023年10月17日

试验速览

暂无简介。

•The exclusion criteria included the administration of chemotherapy, radiotherapy, or biological therapy in the 4 weeks, 2 weeks for palliative radiotherapy and kinase inhibitors prior to enrollment Other active malignancies; history or presence of interstitial lung disease; presence of symptomatic brain metastasis; history within 6 months before enrollment or presence of severe cardiovascular or cerebrovascular disease, pulmonary thrombosis, deep vein thrombosis, or other clinically severe pulmonary disease; any of the following complications, including clinically severe infections requiring systemic administration of an antimicrobial agent, antiviral agent or other agents; presence of chronic diarrhea, inflammatory bowel disease or partial ileus; presence of peptic ulcer; fluid retention requiring treatment; uncontrolled diabetes mellitus/hypertension; psychiatric symptoms; appositive test for hepatitis B virus surface antigen, hepatitis C virus antibody or human immunodeficiency virus antibody.

发起方

Department of Medical Oncology, Kindai University Faculty of Medicine